^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AREG overexpression

    i
    Other names: AREG, AREGB, SDGF, Amphiregulin
    Entrez ID:
    374
    Related biomarkers:
    Expression
    8ms
    miR-33a-3p regulates METTL3-mediated AREG stability and alters EMT to inhibit pancreatic cancer invasion and metastasis. (PubMed, Sci Rep)
    In summary, this research reveals that miR-33a-3p inhibits mA-induced stabilization of AREG by targeting METTL3, which plays a key role in the aggressive progression of PC. AREG could be a potential target for PC treatment.
    Journal
    |
    AREG (Amphiregulin) • EGF (Epidermal growth factor) • METTL3 (Methyltransferase Like 3) • MIR33A (MicroRNA 33a)
    |
    AREG overexpression
    1year
    The molecular landscape of breast mucoepidermoid carcinoma. (PubMed, Cancer Med)
    Triple-negativity and PD-L1 positivity suggest a window of opportunity for immunotherapy in these patients. The EGFR/AREG axis activation, coupled with the mutational patterns in PI3K/AKT/mTOR and cell cycle pathways warrants caution in considering MECs as low-risk neoplasms.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • mTOR (Mechanistic target of rapamycin kinase) • EWSR1 (EWS RNA Binding Protein 1) • AREG (Amphiregulin) • MAML2 (Mastermind Like Transcriptional Coactivator 2)
    |
    TP53 mutation • EGFR overexpression • AREG overexpression • MTOR mutation
    |
    PD-L1 IHC 22C3 pharmDx
    over3years
    Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer. (PubMed, J Thorac Oncol)
    These findings indicate the potential of novel therapies targeting both ALK and EGFR for the treatment of ALK-TKI-resistant LMC in ALK-rearranged NSCLC.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • AREG (Amphiregulin)
    |
    ALK rearrangement • AREG overexpression
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib) • erlotinib • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib)
    over3years
    Amphiregulin expression is a predictive biomarker for EGFR inhibition in metastatic colorectal cancer: combined analysis of three randomized trials. (PubMed, Clin Cancer Res)
    High AREG mRNA expression is a favorable prognostic biomarker for mCRC which interacted significantly with efficacy of anti-EGFR treatment.
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • AREG (Amphiregulin) • EREG (Epiregulin)
    |
    BRAF mutation • PIK3CA mutation • AREG overexpression • AREG expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab)
    4years
    [VIRTUAL] High amphiregulin mRNA expression is a strong prognostic biomarker with response to cetuximab in FIRE-1, CIOX, and FIRE-3. (ASCO 2020)
    AREG and EREG mRNA expression by RTqPCR in relation to housekeeping genes were available from 688 patients of three RCT (FIRE-1, n = 192, FUFIRI vs. mIrOx; CIOX, n = 113, cetuximab + CAPIRI/CAPOX; FIRE-3, n = 383, FOLFIRI+cetuximab/bevacizumab) and were normalized to their respective range of each trial with median and 3rd quartile as threshold values. High AREG mRNA expression appeared as strong prognostic biomarker in mCRC. Positive predictive information might exist for cetuximab treatment. Research Funding: None
    AREG (Amphiregulin) • EREG (Epiregulin)
    |
    AREG overexpression • AREG expression
    |
    Avastin (bevacizumab) • Erbitux (cetuximab)